Does losartan reduce the risk of stroke in patients with hypertension?

Nature Clinical Practice Cardiovascular Medicine

Volumn 2, Issue 5, 2005, Pages 236-237

  Unger, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Atenolol; Losartan; Stroke

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LOSARTAN; PLACEBO; THIAZIDE DIURETIC AGENT;

BLOOD ANALYSIS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; METHODOLOGY; MULTICENTER STUDY; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SHORT SURVEY; SITTING; STROKE; SYSTOLIC BLOOD PRESSURE; URINALYSIS;

EID: 20544476171     PISSN: 17434297     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpcardio0197     Document Type: Short Survey

References (5)

1. Dahlöf B et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995-1003
2. Dai WJ et al. (1999) Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 30: 2391-2398
3. Iwai M et al. (2004) Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 110: 843-848
4. Li J et al. (2005) Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 19: 617-619
5. Carlberg B et al. (2004) Atenolol in hypertension: is it a wise choice? Lancet 364: 1684-1689